The CXCR4 inhibitor X4-136 enhances the in vivo efficacy of established drugs against preclinical models of aggressive pediatric acute lymphoblastic leukemia

Richard B Lock, Kathryn Evans, Connor D Jones, Nairamni El-Zein, Stephen W Erickson, Sarah Beaussant-Cohen, E Lynne Kelley, Beverly A Teicher, Malcolm A Smith,1
1Children’s Cancer Institute, School of Women’s and Children’s Health, UNSW Sydney, Sydney, Australia; 2RTI International, Research Triangle Park, NC; 3X4 Pharmaceuticals, Inc., Cambridge, MA; 4National Cancer Institute, Bethesda, MD.

Abstract C004

Clinical Cancer Research 22(17):3812-3820. 26 August 2016

3. Results

3.1. Efficacy of individual drugs and combinations

3.2. Duration of response

3.3. Results (continued)

3.4. Discussion and Conclusions

3.5. References

3.6. More Information

1. Introduction

2. Study Methods

3. Results

Table 1. In vivo responses of parental ALL-PDXs to X4-136 alone and in combination with VXL.

Figure 1. Expression of CXCR4 on the cell surface of pediatric ALL-PDXs and cell lines. Cell surface CXCR4 was quantified using the CELLQUANT calibration and represented as specific antibody binding capacity (sABC).

Figure 2. Responses of ALL-PDXs to X4-136 alone or in combination with VXL in vivo. Cell lines. In vivo combinations were tested for 15-28 days (T/C 1.4 - 2.2). However, no objective responses were achieved.

Figure 3. Changes in tumor burden of established ALL-PDXs treated with X4-136 alone or in combination with VXL. The X4-136 combination significantly decreased leukemic infiltration in the BM compared with X4-136 and VXL alone.

Figure 4. Changes in tumor burden of established ALL-PDXs treated with X4-136 alone or in combination with VXL. The X4-136 combination significantly decreased leukemic infiltration in the BM compared with X4-136 and VXL alone.

Figure 5. Box plots showing changes in tumor burden of established ALL-PDXs treated with X4-136 alone or in combination with VXL. The X4-136 combination significantly decreased leukemic infiltration in the BM compared with X4-136 and VXL alone.

Figure 6. Changes in tumor burden of established ALL-PDXs treated with X4-136 alone or in combination with VXL. The X4-136 combination significantly decreased leukemic infiltration in the BM compared with X4-136 and VXL alone.

Table 1. In vivo responses of parental ALL-PDXs to X4-136 alone and in combination with VXL.

Table 1. In vivo responses of parental ALL-PDXs to X4-136 alone and in combination with VXL.

Table 1. In vivo responses of parental ALL-PDXs to X4-136 alone and in combination with VXL.

Table 1. In vivo responses of parental ALL-PDXs to X4-136 alone and in combination with VXL.

Table 1. In vivo responses of parental ALL-PDXs to X4-136 alone and in combination with VXL.

Table 1. In vivo responses of parental ALL-PDXs to X4-136 alone and in combination with VXL.

Table 1. In vivo responses of parental ALL-PDXs to X4-136 alone and in combination with VXL.